HTML Microdata document

This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n5	http://linked.opendata.cz/resource/AHFS/
foaf	http://xmlns.com/foaf/0.1/
n25	http://linked.opendata.cz/resource/mesh/concept/
n10	http://linked.opendata.cz/resource/drugbank/company/
n16	http://linked.opendata.cz/resource/drugbank/dosage/
n17	http://linked.opendata.cz/resource/drugbank/drug/DB00995/identifier/kegg-drug/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00995/identifier/drugbank/
n19	http://bio2rdf.org/drugbank:
n11	http://linked.opendata.cz/resource/drugbank/drug/DB00995/identifier/national-drug-code-directory/
adms	http://www.w3.org/ns/adms#
n14	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n15	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00995/identifier/chebi/
n24	http://linked.opendata.cz/ontology/mesh/
n3	http://linked.opendata.cz/ontology/drugbank/
n23	http://www.drugs.com/cdi/
n8	http://linked.opendata.cz/resource/drugbank/property/
n26	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n7	http://linked.opendata.cz/resource/drugbank/drug/DB00995/identifier/wikipedia/
xsdh	http://www.w3.org/2001/XMLSchema#
n12	http://linked.opendata.cz/resource/drugbank/drug/DB00995/identifier/pharmgkb/
n21	http://linked.opendata.cz/resource/atc/
n4	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00995
rdf:type: n3:Drug
n3:description: Auranofin is a organogold compound classified by the World Health Organization as an antirheumatic agent. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.
n3:dosage: n16:271B4BDF-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # Jeon KI, Byun MS, Jue DM: Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med. 2003 Apr 30;35(2):61-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12754408 # Kim IS, Jin JY, Lee IH, Park SJ: Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol. 2004 Jun;142(4):749-55. Epub 2004 May 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15159275 # Venardos K, Harrison G, Headrick J, Perkins A: Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart. Clin Exp Pharmacol Physiol. 2004 May-Jun;31(5-6):289-94. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15191400 # Hafejee A, Winhoven S, Coulson IH: Jessner's lymphocytic infiltrate responding to oral auranofin. J Dermatolog Treat. 2004 Sep;15(5):331-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15370403 # Rigobello MP, Folda A, Baldoin MC, Scutari G, Bindoli A: Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic Res. 2005 Jul;39(7):687-95. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16036347
n3:group: approved
n3:indication: Used in the treatment of active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis.
n3:manufacturer: n10:271B4BDD-363D-11E5-9242-09173F13E4C5
owl:sameAs: n14:DB00995 n19:DB00995
dcterms:title: Auranofin
adms:identifier: n7:Auranofin n11:65483-093-06 n12:PA448510 n17:D00237 n18:2922 n20:DB00995
n3:mechanismOfAction: Exactly how auranofin works is not well understood. It may act as an inhibitor of kappab kinase and thioredoxin reductase which would lead to a decreased immune response and decreased free radical production, respectively. In patients with inflammatory arthritis, such as adult and juvenile rheumatoid arthritis, gold salts can decrease the inflammation of the joint lining. This effect can prevent destruction of bone and cartilage.
n3:packager: n10:271B4BDA-363D-11E5-9242-09173F13E4C5 n10:271B4BDB-363D-11E5-9242-09173F13E4C5 n10:271B4BDC-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination: Approximately 60% of the absorbed gold (15% of the administered dose) from a single dose of auranofin is excreted in urine; the remainder is excreted in the feces.
n3:synonym: (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate Auroafen Triethylphosphine gold Auranofine Auranofinum 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold Ridaura Auranofina
n3:toxicity: Oral, rat: LD<sub>50</sub> = > 2000 mg/kg. Symptoms of overdose may include diarrhoea, vomiting, abdominal cramps, and symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing).
n4:hasAHFSCode: n5:60-00-00
n3:foodInteraction: Take with food to reduce irritation.
n3:synthesisReference: David T. Hill, Ivan Lantos, Blaine M. Sutton, "Process and intermediate for preparing auranofin." U.S. Patent US4133952, issued January, 1972.
n24:hasConcept: n25:M0001971
foaf:page: n23:auranofin.html n26:rid1379.shtml
n3:IUPAC-Name: n8:271B4BE4-363D-11E5-9242-09173F13E4C5
n3:InChI: n8:271B4BEA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n8:271B4BE9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n8:271B4BE6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n8:271B4BE7-363D-11E5-9242-09173F13E4C5
n3:SMILES: n8:271B4BE8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n8:271B4BE2-363D-11E5-9242-09173F13E4C5
n3:logP: n8:271B4BE3-363D-11E5-9242-09173F13E4C5 n8:271B4BE0-363D-11E5-9242-09173F13E4C5
n3:logS: n8:271B4BE1-363D-11E5-9242-09173F13E4C5
n4:hasATCCode: n21:M01CB03
n3:H-Bond-Acceptor-Count: n8:271B4BF0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n8:271B4BF1-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n8:271B4BEB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n8:271B4BEC-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n8:271B4BEE-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n8:271B4BED-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n8:271B4BEF-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 34031-32-8
n3:category
n3:containedIn: n15:271B4BDE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n8:271B4BF5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n8:271B4BF7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n8:271B4BF8-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n8:271B4BF9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n8:271B4BF4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n8:271B4BF3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n8:271B4BF6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n8:271B4BE5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n8:271B4BF2-363D-11E5-9242-09173F13E4C5